Original Articles Vol. 3 No. 3 (2026): Bioscience Insights Published 2026-11-20

GENDER DIFFERENCES IN ADVERSE EVENT REPORTING DURING BIOLOGIC THERAPY FOR AUTOIMMUNE DISEASE

Authors

  • Hafiza Saba Idrees Senior Clinical Pharmacist, Lecturer, College of Nursing, National Hospital & Medical Centre-DHA Lahore Pakistan, University College of Pharmacy-University of the Punjab, Lahore –Pakistan, Riphah International University, Lahore, Pakistan Pakistan Author
  • Zunaira Muzzamil Medical Officer, Gastroenterology and Liver Transplant, Bahria International Hospital Orchard, Lahore, Pakistan Pakistan Author
  • Ali Nawaz MBBS, Hunan University of Chinese Medicine, China Pakistan Author
  • Muhammad Hassan Alvi Pharm D, Green International University, Lahore, Pakistan Pakistan Author
  • Sehrish Alam Consultant Pharmacist, Community Pharmacy, Karachi, Pakistan Pakistan Author
  • Adeeba Shahid Pharm D, Green International University, Lahore, Pakistan Pakistan Author
0 views 0 downloads

Abstract

Background: Biologic therapies have significantly improved the management of autoimmune diseases. However, adverse events remain an important concern during treatment. Differences between men and women in adverse event reporting have been described, although the reasons for these differences are not fully understood.

Objective: To assess gender differences in adverse event reporting among patients receiving biologic therapy for autoimmune diseases in tertiary care hospitals in Lahore, Pakistan.

Study type: Cross-sectional multicenter study

Methods: A multicenter cross-sectional study was designed to include adult patients with autoimmune diseases who had received biologic therapy for at least three months. Data were collected using a structured questionnaire covering demographic characteristics, clinical information, treatment history, and adverse events. Gender-based differences in adverse event reporting were assessed using appropriate statistical tests. Multivariable logistic regression was planned to identify factors independently associated with adverse event reporting.

Results: The study included 423 patients, comprising 282 women and 141 men. Adverse events were reported more frequently among women than men. Injection-site reactions and other treatment-related symptoms were among the commonly reported events. The observed differences suggest that gender may be associated with adverse event reporting; however, the influence of clinical characteristics, treatment exposure, and reporting behaviour requires further investigation.

Conclusion: Gender differences may contribute to variations in adverse event reporting among patients receiving biologic therapy for autoimmune diseases. Understanding these differences may improve patient counselling, treatment monitoring, and pharmacovigilance practices.

Keywords

  • Adverse drug reactions; biologic therapy; autoimmune diseases; gender differences; pharmacovigilance; Pakistan

Views & Downloads Statistics (Last 12 Months)

Monthly performance and trends of article views and downloads

Views (12 months)0
Downloads (12 months)0
Article Views PDF Downloads